Sources of regional variation in medicare part D drug spending

New England Journal of Medicine

Volumn 366, Issue 6, 2012, Pages 530-538

  Donohue, Julie M ^a   Morden, Nancy E ^e,f   Gellad, Walid F ^b,c,d   Bynum, Julie P ^e   Zhou, Weiping ^e   Hanlon, Joseph T ^b,c   Skinner, Jonathan ^e,f,g  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d RAND CORPORATION   (United States)

^e DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g Dartmouth College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRESCRIPTION DRUG; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

AGED; ARTICLE; COST CONTROL; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE CONCEPTS; HUMAN; MALE; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; REGIONAL VARIATION; UNITED STATES;

EID: 84856804470     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa1104816     Document Type: Article

References (37)

1. Fisher ES, Bynum JP, Skinner JS. Slowing the growth of health care costs - lessons from regional variation. N Engl J Med 2009;360:849-52.
2. Sutherland JM, Fisher ES, Skinner JS. Getting past denial - the high cost of health care in the United States. N Engl J Med 2009;361:1227-30.
3. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med 2003;138:273-87. (Pubitemid 36205924)
4. Idem. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med 2003;138:288-98.
5. Yasaitis L, Fisher ES, Skinner JS, Chandra A. Hospital quality and intensity of spending: is there an association? Health Aff (Millwood) 2009;28(4):w566-w572.
6. Zhang Y, Baicker K, Newhouse JP. Geographic variation in Medicare drug spending. N Engl J Med 2010;363:405-9.
7. Donohue JM, Fischer MA, Huskamp HA, Weissman JS. Savings associated with increased use of Consumer Reports best buy drugs. Health Serv Res 2008;43:1557-75.
8. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004;291:1850-6. (Pubitemid 38509497)
9. Lexi-Data Basic database (Lexicomp). Denver: Cerner Multum (http://www.lexi.com/businesses/solutions/clinicaldecision- support).
10. Census 2000, summary file: American fact finder. Washington, DC: Census Bureau (http://factfinder.census.gov/servlet/DTGeoSearchByListServlet?ds-name= DEC-2000-SF3-U&-lang=en&-ts=283785721496).
11. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008;148:16-29. (Pubitemid 351664943)
12. Dartmouth Medical School Center for the Evaluative Clinical Sciences. The Dartmouth atlas of health care. Chicago: American Hospital Publishing, 1998.
13. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. Rockville, MD: Agency for Healthcare Research and Quality (http://www.ahrq.gov/qual/medicareindicators/ medicareindicators2.htm).
14. RxHCC model software. Baltimore: Centers for Medicare & Medicaid Services (https://www.cms.gov/MedicareAdvtgSpec RateStats/06-Risk-adjustment. asp#TopOfPage).
15. Robst J, Levy JM, Ingber MJ. Diagnosis-based risk adjustment for Medicare prescription drug plan payments. Health Care Financ Rev 2007;28:15-30. (Pubitemid 47173624)
16. Welch HG, Sharp SM, Gottlieb DJ, Skinner JS, Wennberg JE. Geographic variation in diagnosis frequency and risk of death among Medicare beneficiaries. JAMA 2011;305:1113-8.
17. Song Y, Skinner JS, Bynum JP, Sutherland J, Wennberg JE, Fisher ES. Regional variations in diagnostic practices. N Engl J Med 2010;363:45-53. [Erratum, N Engl J Med 2010;363:198.]
18. Oaxaca R. Male-female wage differentials in urban labor markets. Int Econ Rev 1973;14:693-703.
19. MaCurdy T, Gibbs J, Theobald N, Deleire T, Kautz T, O'Brien-Strain M. Geographic variation in drug prices and spending in the Part D program: report for the Centers for Medicare & Medicaid Services. Burlingame, CA: Acumen, 2009.
20. Fact sheet: the Medicare prescription drug benefit. Washington, DC: Kaiser Family Foundation, 2008.
21. Anthony JDL, Herndon MB, Gallagher PM, et al. How much do patients' preferences contribute to resource use? Health Aff (Millwood) 2009;28:864-73. [Erratum, Health Aff (Millwood) 2009;28:1233.]
22. Medicare prescription drug plans in 2010 and key changes over five years. Washington, DC: Kaiser Family Foundation, 2010.
23. Generic drug utilization in the Medicare Part D program. Washington, DC: Department of Health and Human Services, Office of the Inspector General, 2007.
24. Shrank WH, Stedman M, Ettner SL, et al. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. J Gen Intern Med 2007;22:1298-304. (Pubitemid 47247307)
25. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349:2224-32. (Pubitemid 37485139)
26. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006;166:332-7. (Pubitemid 43244321)
27. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26.
28. Generic drugs revisited. The Medical Letter on Drugs and Therapeutics. October 19, 2009.
29. Matchar DB, McCrory DC, Orlando LA, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating essential hypertension. Rockville, MD: Agency for Healthcare Research and Quality, 2007.
30. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48. (Pubitemid 351688350)
31. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906. [Erratum, N Engl J Med 2004;350:203.] (Pubitemid 37409706)
32. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
33. Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf 2004;13:207-14. (Pubitemid 38514834)
34. Idem. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res 2003;38:1051-63.
35. Gellad WF, Good CB, Lowe JC, Donohue JM. Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System. Am J Manag Care 2010;16:741-50.
36. Spinewine A, Schmader K, Barber N, Hughes C, Lapane KL, Hanlon JT. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007;370:173-84. (Pubitemid 47049724)
37. Medicare prescription drug benefit fact sheet. Menlo Park, CA: Kaiser Family Foundation, 2007.